Optic IconOptic Logo
|
SearchCollectionsBenchmarks

GemCis/nab-P

4 abstracts

Abstract
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.
Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, CHA University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).
Org: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, Ziauddin Medical University, Karachi, Pakistan, Canyon Vista Medical Center, Sierra Vista, AZ, University of Arizona, Tucson, AZ, Rashid Latif Medical College, Lahore, Pakistan,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.
Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
Org: Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Chinese Academy of Sciences,